Please assess the completion status of the following clinical trial:

Trial Title: DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
SELECTED INCLUSION CRITERIA:~1. Subjects must be competent to provide written informed consent;~2. Subjects must have completed the Maintenance Period of the DAR-312 study.~SELECTED EXCLUSION CRITERIA:~1. Subjects who discontinue treatment with study drug prior to the end of the Maintenance Period in DAR-312 due to a study drug-related AE;~2. Subjects who experience a study drug-related serious adverse event (SAE) during the DAR-312 study.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Darusentan (Type: EXPERIMENTAL): Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
- Guanfacine (Type: ACTIVE_COMPARATOR): Guanfacine 1 mg capsules administered orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).